Mark Dawson

Head of Roche Pharma Research and Early Development · Roche Group

Pharmaceuticals and Diagnostics

Mark Dawson leads Roche Pharma Research and Early Development. A haematologist and molecular-biology researcher, he joined Roche after clinical, academic and research leadership at the Peter MacCallum Cancer Centre and the University of Melbourne.

Last reviewed: Nov 10, 2026

Mark Dawson

Head of Roche Pharma Research and Early Development
Roche Group

Last Reviewed: November 10, 2026

Executive Summary

Mark Dawson leads Roche Pharma Research and Early Development. A haematologist and molecular-biology researcher, he joined Roche after clinical, academic and research leadership at the Peter MacCallum Cancer Centre and the University of Melbourne.

Career Highlights

  • Joined Roche’s pRED leadership and enlarged executive committee on May 1, 2026.

  • Combined consultant haematology with research-program leadership in Melbourne.

  • Received the 2020 Frank Fenner Prize for Life Scientist of the Year.

Professional Journey

Dawson completed his medical training at the University of Melbourne in 1999. His early clinical work included internship and residency at St. Vincent’s Hospital Melbourne from 2000 to 2003, followed by specialist haematology and haematopathology training at the Alfred Hospital.

He moved to Cambridge for doctoral research in molecular biology and completed a PhD in the subject. Alongside his research, he served as a consultant haematologist at Addenbrooke’s Hospital from 2007 to 2014. His Cambridge work included a Wellcome Beit Fellowship at the Cambridge Institute for Medical Research and the Gurdon Institute.

In 2014, he returned to Melbourne as a consultant at the Peter MacCallum Cancer Centre and Royal Melbourne Hospital. He became a University of Melbourne professor in 2016, led translational haematology from 2016 to 2018 and then headed Cancer Biology and Therapeutics through 2025. He was also Peter Mac’s associate director of research from 2019 to 2026.

His research has examined how chromatin regulation and epigenetic mechanisms contribute to cancer. The Australian government’s 2020 prize citation recognized his work on targeting epigenetic pathways, including BET proteins, and its progression from laboratory discovery toward clinical trials. He received the Frank Fenner Prize for Life Scientist of the Year that year.

Dawson joined Roche as head of Pharma Research and Early Development on May 1, 2026, based in Basel. The appointment also brought him onto Roche’s enlarged Corporate Executive Committee.

Education

Dawson earned his MBBS and Bachelor of Medical Science at the University of Melbourne in 1999 and completed a PhD in molecular biology at the University of Cambridge.